Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse
Joseph C. Cheng, Aiping Bai, Thomas H. Beckham, S. Tucker Marrison, Caroline L. Yount, Katherine Young, Ping Lu, Anne M. Bartlett, Bill X. Wu, Barry J. Keane, Kent E. Armeson, David T. Marshall, Thomas E. Keane, Michael T. Smith, E. Ellen Jones, Richard R. Drake Jr., Alicja Bielawska, James S. Norris, Xiang Liu
Joseph C. Cheng, Aiping Bai, Thomas H. Beckham, S. Tucker Marrison, Caroline L. Yount, Katherine Young, Ping Lu, Anne M. Bartlett, Bill X. Wu, Barry J. Keane, Kent E. Armeson, David T. Marshall, Thomas E. Keane, Michael T. Smith, E. Ellen Jones, Richard R. Drake Jr., Alicja Bielawska, James S. Norris, Xiang Liu
View: Text | PDF
Research Article Oncology

Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse

  • Text
  • PDF
Abstract

Escape of prostate cancer (PCa) cells from ionizing radiation–induced (IR-induced) killing leads to disease progression and cancer relapse. The influence of sphingolipids, such as ceramide and its metabolite sphingosine 1-phosphate, on signal transduction pathways under cell stress is important to survival adaptation responses. In this study, we demonstrate that ceramide-deacylating enzyme acid ceramidase (AC) was preferentially upregulated in irradiated PCa cells. Radiation-induced AC gene transactivation by activator protein 1 (AP-1) binding on the proximal promoter was sensitive to inhibition of de novo ceramide biosynthesis, as demonstrated by promoter reporter and ChIP-qPCR analyses. Our data indicate that a protective feedback mechanism mitigates the apoptotic effect of IR-induced ceramide generation. We found that deregulation of c-Jun induced marked radiosensitization in vivo and in vitro, which was rescued by ectopic AC overexpression. AC overexpression in PCa clonogens that survived a fractionated 80-Gy IR course was associated with increased radioresistance and proliferation, suggesting a role for AC in radiotherapy failure and relapse. Immunohistochemical analysis of human PCa tissues revealed higher levels of AC after radiotherapy failure than those in therapy-naive PCa, prostatic intraepithelial neoplasia, or benign tissues. Addition of an AC inhibitor to an animal model of xenograft irradiation produced radiosensitization and prevention of relapse. These data indicate that AC is a potentially tractable target for adjuvant radiotherapy.

Authors

Joseph C. Cheng, Aiping Bai, Thomas H. Beckham, S. Tucker Marrison, Caroline L. Yount, Katherine Young, Ping Lu, Anne M. Bartlett, Bill X. Wu, Barry J. Keane, Kent E. Armeson, David T. Marshall, Thomas E. Keane, Michael T. Smith, E. Ellen Jones, Richard R. Drake Jr., Alicja Bielawska, James S. Norris, Xiang Liu

×

Figure 8

Radiosensitization of PCa IR via AC inhibition.

Options: View larger image (or click on image) Download as PowerPoint
Radiosensitization of PCa IR via AC inhibition.
(A) Protein expression i...
(A) Protein expression in PPC-1 cells treated with AC small molecule inhibitor LCL521 (5 μM, 24 hours). Mean densitometry of normalized AC expression is shown. (B) 72-hour-dose responses of 22Rv1, DU 145, PPC-1, and WPMY-1 cell lines to LCL521 exposure. (C) Isobologram of LCL521 and IR combination therapy based on PPC-1 cell treatment for 8 days (single IR fraction at day 0; LCL521 treatment at days 0 and 4). Solid line represents theoretical line of additivity ± SD (dashed lines). (D) Ester bond hydrolysis of prodrug LCL521 into LCL522 and secondary ester bond hydrolysis into the active AC inhibitor, B13, in PPC-1 xenografts 6 hours after intraperitoneal administration (75 mg/kg). Subcutaneous PPC-1 xenografts grown on the flanks of athymic nu/nu mice were subjected to 6 × 5 Gy fractions of focal γ irradiation (red triangles) in combination with LCL521 (75 mg/kg, i.p. injection) or cremophor EL (vehicle control). (E) Xenograft volumes and (F) overall survival were monitored, and representative xenografts are depicted at day 108; n per group noted parenthetically.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts